Femke M. de Man

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Linda M. Henricks, Carin A.T.C. Lunenburg, Femke M. de Man et al. · The Lancet Oncology · 2018 · 403 citations · Full text

Medicine, Prospective Safety Analysis, Cancer Management +9

Drug–drug interactions in patients treated for cancer: a prospective study on clinical interventions

Roelof W. F. van Leeuwen, Frank G. A. Jansman, Patricia M. L. A. van den Bemt et al. · Annals of Oncology · 2015 · 135 citations · Full text

Drug Interactions, Medicine, Cancer Management +8

A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapy

Linda M. Henricks, Carin A.T.C. Lunenburg, Femke M. de Man et al. · European Journal of Cancer · 2018 · 87 citations · Full text

Upfront Dpyd, Medicine, Metronomic Therapy +8

Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study

Mirjam de With, Jonathan E. Knikman, Femke M. de Man et al. · Clinical Pharmacology & Therapeutics · 2022 · 54 citations · Full text

UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients

Emma C. Hulshof, Mirjam de With, Femke M. de Man et al. · European Journal of Cancer · 2022 · 48 citations · Full text

Drug Safety, Prospective Safety, Poor Metaboliser Patients +5